Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080420519> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W3080420519 abstract "In order to exploit the complex tumour microenvironment, immunoreactivity in a multitude of cell-based assays is required to predict mode of action (MOA), pharmacodynamics, and efficacy downstream. We have developed an integrated approach starting with single cell and co-culture cell-based assays in 2D and 3D formats, followed by an in vivo set-up based on humanized mice to monitor an immunotherapeutic9s interaction with specific cell types such as T cells including CAR-T cells, natural killer cells, macrophages, dendritic cells, neutrophils, and fibroblasts. Rituximab, a monoclonal antibody against CD20, is mainstay in the therapy for a broad variety of B-cell malignancies. Its MOA is not fully understood as direct signalling, complement dependent cellular cytotoxicity and antibody dependent cellular cytotoxicity (ADCC) all seem to have an impact. To elucidate the share and effect each of those mechanism has, we tested Rituximab in our immuno-oncology translational platform. Furthermore, our immuno-oncology platform was utilized to assess efficacy, bystander effects and off-target toxicity of a CD19 CAR-T cell therapy. In vitro assays for efficacy and bystander effect involved co-culture of the CAR-T cells with a mixture of non-target expressing cells and mid to high target antigen expressing cells, where T cell activation and cell death of both target cell types was quantified. Beyond efficacy the assay platforms were used to examine the influence of the therapy, antibodies or CAR-T cells, on normal human cells. These in vitro assays utilizing primary human cells from healthy tissue and/or differentiated iPCS-derived cells were used to assess cytotoxicity. The primary tissues were selected based on their potential safety risk by either expressing low levels of the target antigen or being major organs to de-risk for off-target effects. The results from our in vitro screen were validated in a xenograft in vivo system in the presence and absence of human immune cells. Four cell line derived xenografts were tested in vivo in immunocompromised mice subcutaneously and disseminated. The presence of human immune cells enhanced the antitumoral activity of Rituximab markedly, although the targeted effect of Rituximab induced already a significant prolongation in the overall survival (p Citation Format: Shilina Roman, Julia Schuler, Sanne Holt, Jeroen DeGroot, Omar Aziz, Ian Waddell. An integrated in vitro and in vivo approach providing insights in immune modulation [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6705." @default.
- W3080420519 created "2020-09-01" @default.
- W3080420519 creator A5015762832 @default.
- W3080420519 creator A5034114497 @default.
- W3080420519 creator A5034493142 @default.
- W3080420519 creator A5074500553 @default.
- W3080420519 creator A5082658345 @default.
- W3080420519 creator A5085468214 @default.
- W3080420519 date "2020-08-13" @default.
- W3080420519 modified "2023-09-25" @default.
- W3080420519 title "Abstract 6705: An integratedin vitroandin vivoapproach providing insights in immune modulation" @default.
- W3080420519 doi "https://doi.org/10.1158/1538-7445.am2020-6705" @default.
- W3080420519 hasPublicationYear "2020" @default.
- W3080420519 type Work @default.
- W3080420519 sameAs 3080420519 @default.
- W3080420519 citedByCount "0" @default.
- W3080420519 crossrefType "proceedings-article" @default.
- W3080420519 hasAuthorship W3080420519A5015762832 @default.
- W3080420519 hasAuthorship W3080420519A5034114497 @default.
- W3080420519 hasAuthorship W3080420519A5034493142 @default.
- W3080420519 hasAuthorship W3080420519A5074500553 @default.
- W3080420519 hasAuthorship W3080420519A5082658345 @default.
- W3080420519 hasAuthorship W3080420519A5085468214 @default.
- W3080420519 hasConcept C121332964 @default.
- W3080420519 hasConcept C123079801 @default.
- W3080420519 hasConcept C203014093 @default.
- W3080420519 hasConcept C24890656 @default.
- W3080420519 hasConcept C2991678113 @default.
- W3080420519 hasConcept C41008148 @default.
- W3080420519 hasConcept C71924100 @default.
- W3080420519 hasConcept C8891405 @default.
- W3080420519 hasConceptScore W3080420519C121332964 @default.
- W3080420519 hasConceptScore W3080420519C123079801 @default.
- W3080420519 hasConceptScore W3080420519C203014093 @default.
- W3080420519 hasConceptScore W3080420519C24890656 @default.
- W3080420519 hasConceptScore W3080420519C2991678113 @default.
- W3080420519 hasConceptScore W3080420519C41008148 @default.
- W3080420519 hasConceptScore W3080420519C71924100 @default.
- W3080420519 hasConceptScore W3080420519C8891405 @default.
- W3080420519 hasLocation W30804205191 @default.
- W3080420519 hasOpenAccess W3080420519 @default.
- W3080420519 hasPrimaryLocation W30804205191 @default.
- W3080420519 hasRelatedWork W1964519834 @default.
- W3080420519 hasRelatedWork W2007672013 @default.
- W3080420519 hasRelatedWork W2161743636 @default.
- W3080420519 hasRelatedWork W2386061805 @default.
- W3080420519 hasRelatedWork W2416648577 @default.
- W3080420519 hasRelatedWork W2472592681 @default.
- W3080420519 hasRelatedWork W2582143511 @default.
- W3080420519 hasRelatedWork W2584545829 @default.
- W3080420519 hasRelatedWork W2789730463 @default.
- W3080420519 hasRelatedWork W4280620694 @default.
- W3080420519 isParatext "false" @default.
- W3080420519 isRetracted "false" @default.
- W3080420519 magId "3080420519" @default.
- W3080420519 workType "article" @default.